

HOSTED BY



Contents lists available at ScienceDirect

Alexandria Journal of Medicine

journal homepage: <http://www.elsevier.com/locate/ajme>

Parathormone (PTH) is strongly related to left ventricular mass index (LVMI) in hypertensives, obese, and normal control



Samir Naim Assaad^a, Aliaa Ali El-Aghoury^a, Eman M. El-Sharkawy^b, Tamer Mohamed Elsherbiny^{a,*}, Ahmed Abdelhameed Osman^a

^a Internal Medicine Department, Alexandria Faculty of Medicine, Egypt

^b Cardiology Department, Alexandria Faculty of Medicine, Egypt

1. Introduction

Left ventricular hypertrophy [LVH] is defined on a normative basis; based on 2 standard deviations above the mean left ventricular mass [LVM] in the general population or based on the healthy population without obesity or hypertension. LVH confers an increased risk of cardiovascular and all-cause mortality in the general population.^{1,2}

Obesity is reaching an epidemic scale worldwide. Obesity cardiomyopathy is defined as myocardial disease in obese individuals that cannot be explained by diabetes mellitus, hypertension, coronary artery disease or other etiologies, the presentation of this condition varies from asymptomatic left ventricular dysfunction to overt dilated cardiomyopathy. LV remodeling, increased LVM, LVH, and LV dilatation are among the documented cardiac changes in obese individuals.^{3–5}

Known mechanisms to explain obesity cardiomyopathy include: increased preload and afterload in response to the high metabolic activity of adipose tissue, lipotoxicity in the form of fatty acids and triglycerides accumulation in parenchymal myocytes, hyperleptinemia, hypoadiponectinemia, and proinflammatory state.⁵

Insulin resistance and associated hyperinsulinemia are key players in this condition through 4 mechanisms: insulin binding to myocardial IGF-1 receptors inducing LVH, activation of RAAS with angiotensin II exerting a proliferative hypertrophic action, activation of SNS leading to induction of cardiac fetal program, and finally endothelial dysfunction leading to failure to recruit to myocardial microcirculation in response to stress.⁵

Blood pressure is considered the most important hemodynamic factor in the development and extent of left ventricular hypertrophy. Hypertensive left ventricular hypertrophy is associated with a threefold increase in cardiovascular morbidity and mortality. A powerful relation between LV mass and risk of cardiovascular disease in subjects with uncomplicated untreated essential hypertension, even below the upper normal limits of LV mass values. A

significant relationship continues to exist between left ventricular mass and blood pressure in hypertensives even under treatment.^{6,7}

A relation between LVH, LVMI, and parathormone [PTH] has been demonstrated in clinical and experimental studies. PTH was found to be associated with LVMI in several disease populations including primary hyperparathyroidism, end stage renal disease with secondary hyperparathyroidism, essential hypertension, and patients after aortic valve replacement. The relation between PTH and LVH was not only shown in disease states, but also for general population and elderly population.^{8–16}

Possible mechanisms mediating ventricular hypertrophic effect of PTH can be divided into direct and indirect. Indirectly, high PTH has been shown to be associated with high BMI, systolic, diastolic, and central blood pressures, all are established risk factors for LVH.^{8,17}

Direct mechanisms include: A positive chronotropic action, intact PTH 1–84 with 3 folds greater potency compared to PTH 1–39, stimulates adenylate cyclase leading to increased intracellular cyclic AMP which will activate cardiac L-type Ca²⁺ channels leading to increased L-type Ca²⁺ currents with increased intracellular Ca influx.¹⁸

Increase sinoatrial node automaticity by increasing pace maker currents in SAN.¹⁷ A positive inotropic action, through increasing both heart rate, and coronary blood flow.¹⁷ A direct hypertrophic effect, via activation of protein kinase C and mediated by the functional domain [28–34] e.g. PTH 1–34 or PTH 28–48, through increasing collagen synthesis, increased cellular protein mass, re-expression of fetal proteins like creatine kinase BB.¹⁸

The aim of this work was to study the role of PTH as a determinant of LV mass in hypertensive and/or obese patients.

2. Subjects

The study included 85 subjects of both male and female gender with age between 20 and 50 years. They were classified into 3 groups, group I: 30 obese hypertensive patients, group II: 30 obese non-hypertensive patients, attending the Internal Medicine and the Endocrinology Outpatient Clinics in Alexandria Main University Hospital, and group III: 25 healthy matched subjects that served as a control group.

Peer review under responsibility of Alexandria University Faculty of Medicine.

* Corresponding author.

E-mail address: Tamer_elsherbiny@alexmed.edu.eg (T.M. Elsherbiny).

<https://doi.org/10.1016/j.ajme.2017.10.002>

2090-5068/© 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Alexandria Faculty of Medicine Ethical committee approved the protocol of the study, and all study participants provided a written informed consent after being explained the nature and aim of the study.

Exclusion criteria: subjects with cardiac disease (coronary artery disease, rheumatic heart disease), diabetes mellitus (fasting plasma glucose ≥ 126 mg/dl or the use of antidiabetic drugs), left ventricular systolic dysfunction (EF < 40%), renal diseases, hepatic diseases, other endocrinal dysfunction, receiving anti-hypertensive drugs affecting renin angiotensin aldosterone system were excluded. e.g. angiotensin converting enzyme inhibitors, angiotensin receptor blockers and aldosterone receptor antagonists.

3. Methods

All patients were subjected to the following:

Complete physical examination was performed, including blood pressure measurement. Height, weight, and waist and hip circumferences were measured and BMI was calculated using the formula [weight in kg/height in m²].

Body fat mass percentage was calculated using the Deurenberg equation as follows: [body fat percentage = $1.2 \times \text{BMI} + 0.23 \times \text{age} - 10.8 \times \text{sex} - 5.4$], with age being in years and sex being designated as 1 for male and 0 for female patients.¹⁹

3.1. Biochemical assays

venous sampling was carried out in the morning (8.00–10.00 a.m.) after an overnight fast of 8–10 h. The blood was drawn into an empty tube and then centrifuged for 10 min. The separated serum was used for the following assays: fasting plasma glucose level, lipid profile (triglycerides, cholesterol, HDL-C and LDL-C), renal function tests: serum creatinine and blood urea, total calcium, and phosphorus. Serum parathormone level was also measured by using radioimmunoassay method [DIAsource hPTH-120 min-IRMA Kit, DIAsource ImmunoAssays S.A., Belgium].²⁰

3.2. Echocardiography

echocardiographic imaging was performed using HD11XE echo machine (Philips, USA). Cardiac dimensions and wall thicknesses were measured according to standard recommendations. Left ventricular mass was calculated by the following formula: LVM (Penn) = $1.04[(\text{LVIDD} + \text{PWTD} + \text{IVSTD})^3 - \text{LVIDD}^3] - 13.6$ g and was indexed to body surface area using the Dubois formula [$\text{BSA} = 0.007184 \times \text{H}^{0.725} \times \text{W}^{0.425}$]. Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening were estimated. Left ventricular diastolic function was assessed by measuring mitral flow E wave, A wave, E/A ratio, and mitral annulus tissue velocities.²¹

3.3. Statistical analysis of the data

Data were fed to the computer and analyzed using IBM SPSS software package version 20.0, Armonk, NY: IBM Corp. Comparison between different groups regarding categorical variables was tested using Chi-square test. When more than 20% of the cells have expected count less than 5, correction for chi-square was conducted using Fisher's exact test or Monte Carlo correction. The distributions of quantitative variables were tested for normality. For normally distributed data, comparison between more than two populations were analyzed using *F*-test (ANOVA) and Post Hoc test (Scheffe). For abnormally distributed data, Kruskal Wallis test was used to compare between different groups and pair wise compar-

ison was assessed using Mann-Whitney test. Significance of the obtained results was judged at the 5% level.

4. Results

All studied groups were matched for age and sex. A significant increase in BMI, waist circumference, hip circumference, and body fat percentage was detected among obese patients with or without hypertension in relation to normal individuals [$P = <.001$ for all 4 parameters in both groups I, and II versus control group] [Table 1].

There were statistically significantly higher levels of serum PTH in group I and group II compared to group III [$P = .005, .044$ respectively]. Higher levels were found in group I compared to group II but it did not reach statistical significance [$P = .287$] [Table 1].

There was no statistically significant difference in serum calcium among the three studied groups [Table 1], there was no significant correlation between serum PTH and serum calcium.

LVMI was significantly higher in both group I and group II in comparison to healthy subjects [$P = <.001, <.001$ respectively]. It was also significantly elevated in group I versus group II [$P = <.001$] [Table 1].

A significant positive correlation was found between serum PTH and left ventricular mass index in the three studied groups [$P = <.001, <.001, .005$ for groups I, II, and III respectively] [Fig. 1].

E/A ratio was significantly lower in group I in comparison to group III [$P = .006$]. There was no significant difference in MPAP (mean pulmonary arterial pressure) between the three groups. Left atrial diameter was significantly higher in obese subjects (group I and II) compared to healthy control [$P = .003, <.001$ respectively]. Left atrial volume was significantly higher in group I and group II compared to group III [$P = .008, <.001$ respectively] [Table 1].

5. Discussion

The aim of this work was to study the role of PTH as a determinant of LV mass in hypertensive and/or obese patients. Our results revealed significantly higher levels of serum PTH along with significantly higher LVMI in both group I and group II in comparison to healthy subjects. A significant positive correlation was found between serum PTH and left ventricular mass index in the three studied groups. This correlation is independent of Ca^{2+} and blood pressure as there was no statistically significant difference in serum calcium among the three studied groups, and there was no significant correlation between serum PTH and serum calcium or BP.

In 36 untreated patients with mild to moderate essential hypertension, there was a very significant correlation between LVMI and PTH ($p = .00001$) even after adjustment for mean 24-h systolic and diastolic BPs [$p = .00001, p = .00003$ respectively]. No significant correlations could be found among office systolic and diastolic BPs and PTH, however, there was a significant correlation between mean ambulatory diastolic BP and PTH ($p = .020$). Similar to our findings, there was neither correlation between parathyroid hormone and calcium nor between calcium and LV mass index.¹¹

Furthermore, there was no significant correlation between office systolic and diastolic BPs and LVMI, however, a significant correlation existed between mean ambulatory systolic BP, mean ambulatory diastolic BP, and LVMI ($p = .026, p = .004$ respectively).¹¹

In Another study including 62 essential hypertension patients and 20 normotensive healthy subjects, when classified as hypertensive versus control, PTH was significantly higher in the essential hypertension group ($p < .001$), when classified as those with LVH [LVMI > 125 g/m² in men, and >120 g/m² in women] versus those without, PTH was significantly higher in those with LVH ($p <$

Table 1
Anthropometric, Clinical, Biochemical, and Echocardiographic data of the three studied groups.

Parameter	Group I (n = 30)	Group II (n = 30)	Group III (n = 25)	p
Age (years)	35.5 ± 8.01	33.17 ± 8.97	32.28 ± 7.40	.318
Male	5(16.7%)	11(36.7%)	9(36%)	.163
Female	25(83.3%)	19(63.3%)	16(64%)	
Systolic	141.67 ± 14.16 $p_1 < .001^{\dagger}, p_2 < .001^{\dagger}, p_3 = .654$	117.33 ± 10.48	116.0 ± 5.77	<.001
Diastolic	88.33 ± 7.91 $p_1 < .001^{\dagger}, p_2 < .001^{\dagger}, p_3 = .894$	76.67 ± 8.44	76.40 ± 4.90	<.001
BMI	48.32 ± 7.98 $p_1 = .378, p_2 < .001^{\dagger}, p_3 < .001^{\dagger}$	46.41 ± 11.50	23.64 ± 0.85	<.001
Waist circumference (cm)	125.70 ± 17.43 $p_1 = .252, p_2 < .001^{\dagger}, p_3 < .001^{\dagger}$	121.10 ± 18.79	88.84 ± 4.60	<.001
HIP circumference (cm)	135.77 ± 19.04 $p_1 = .468, p_2 < .001^{\dagger}, p_3 < .001^{\dagger}$	132.33 ± 22.56	100.92 ± 9.24	<.001
Body fat (%)	58.08 ± 10.31 $p_1 = .177, p_2 < .001^{\dagger}, p_3 < .001^{\dagger}$	53.94 ± 15.98	28.95 ± 6.21	<.001
Calcium (mg/dl)	8.81 ± 0.30	8.89 ± 0.35	8.77 ± 0.37	.394
Phosphorus (mg/dl)	3.49 ± 0.36 $p_1 = .001^{\dagger}, p_2 = .493, p_3 = .014^{\dagger}$	3.83 ± 0.41	3.56 ± 0.41	.003
Serum PTH (pg/ml)	29.41 ± 19.44 $p_1 = .287, p_2 = .005^{\dagger}, p_3 = .044^{\dagger}$	23.44 ± 15.54	15.85 ± 10.38	.014
LVEF (%)	67.23 ± 6.66	70.60 ± 6.95	68.12 ± 5.26	.116
LVMI (gm/m ²)	123.72 ± 49.32 $p_1 < .001^{\dagger}, p_2 < .001^{\dagger}, p_3 < .001^{\dagger}$	87.03 ± 30.4	60.9 ± 8.9	<.001
E/A ratio	1.12 ± 0.53 $p_1 = .128, p_2 = .006^{\dagger}, p_3 = .184$	1.27 ± 0.30	1.40 ± 0.10	.023
LAD (mm)	33.38 ± 4.36 $p_1 = .542, p_2 = .003^{\dagger}, p_3 < .001^{\dagger}$	33.98 ± 2.64	30.20 ± 4.27	.001
LAV (ml/m ²)	39.89 ± 11.01 $p_1 = .044^{\dagger}, p_2 = .008^{\dagger}, p_3 < .001^{\dagger}$	44.35 ± 7.34	33.64 ± 5.66	<.001

p: p values comparing between the three groups.

p1: p value for comparing between group I and group II.

p2: p value for comparing between group I and group III.

p3: p value for comparing between group II and group III.

[†] Statistically significant at $p \leq .05$.




Fig. 1. Correlation between serum PTH and left ventricular mass index in the three studied groups

.005). There was a highly significant correlation between LVMI and PTH ($p < .0025$).¹²

Recently, Helvacı et al. in a study that included Twenty-seven newly diagnosed hypertension patients, and 20 healthy individuals as control, they found that PTH level was significantly higher in the hypertensive group ($p = .006$). They also found A significant correlation between LVMI and PTH level in the hypertensive group ($p = .001$). There were no correlations between LVMI, and ambulatory BP, neither between PTH and BP.¹³

It has been suggested that the higher levels of PTH in essential hypertension patients may be due to high levels of serum sodium in patients with essential hypertension, which may be related to excessive dietary salt intake or a defect in the excretion of sodium, which leads to excessive urinary calcium excretion, PTH release increases to compensate for this hypernatremia induced calciuresis.¹³

To the best of our knowledge, our study is the first to show a significant association between PTH and LVMI in obese subjects

without hypertension (group II). This finding may suggest obesity related secondary hyperparathyroidism as a novel mechanism to explain obesity cardiomyopathy.

High PTH [secondary hyperparathyroidism] is well documented in obese individuals with a prevalence ranging from 21% in obese individuals not requiring bariatric surgery to 53% in morbidly obese patients requiring bariatric surgery. Weight was the main determinant of increased PTH in morbid obesity and it decreases significantly with weight loss. Obesity related secondary hyperparathyroidism is independent from 25 OH D3, Ca^{2+} , and renal function. A plausible mechanism may be a direct effect of adipokines, namely leptin, on PTH secretion as leptin has been shown to be a PTH secretagogue.^{22–24}

In 2040 general population cohort of healthy subjects without established cardiovascular disease and not taking antihypertensive drugs, PTH was a significant predictor of LVMI in males and females, older and younger than 60 years of age, respectively [$P < .01$, $< .05$]. It was also observed that serum PTH values in the upper normal range were associated with 14% higher LVMI compared to values in the lower normal range, and the difference was significant in both sexes. Finally, serum PTH was significantly higher in men with LVH compared with the rest of the cohort ($P < .01$).¹⁵

Limitations of this study include lack of ambulatory BP measurement that showed better correlation to PTH than office BP in one study. Another limitation was lack of vitamin D status determination; however, it has been shown that obesity related secondary hyperparathyroidism is independent from vitamin D status.^{11,23}

In conclusion, PTH is strongly related to LVMI in obese patients with or without hypertension as well as normal individuals, independent of Ca^{2+} and blood pressure. To the best of our knowledge, our study is the first to suggest obesity related secondary hyperparathyroidism as a novel mechanism to explain obesity cardiomyopathy.

Conflict of interest

The authors declared that there is no conflict of interest.

References

- Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). *J Am Soc Echocardiogr*. 2015;28:727–754.
- Cuspidi C, Facchetti R, Bombelli M, et al. Prognostic value of left ventricular mass normalized to different body size indexes: findings from the PAMELA population. *J Hypertens*. 2015;33:1082–1089.
- Marie et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014;384:766–781.
- Rider OJ, Francis JM, Ali MK, et al. Determinants of left ventricular mass in obesity; a cardiovascular magnetic resonance study. *J Cardiovasc Magn Reson*. 2009;11:9.
- Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. *Nat Clin Pract Cardiovasc Med*. 2007;4:436–443.
- Missault LH, De Buyzere ML, De Bacquer DD, et al. Relationship between left ventricular mass and blood pressure in treated hypertension. *J Human Hypertens*. 2002;16:61–66.
- Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. *Hypertension*. 2000;35:580–586.
- Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease – a review. *Eur Heart J*. 2004;25:1776–1787.
- Al-Hilali N, Hussain N, Ataia AI, et al. Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis. *Indian J Nephrol*. 2009;19:153–157.
- Randon RB, Rohde LE, Comerlato L, et al. The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. *Braz J Med Biol Res*. 2005;38:1409–1416.
- Bauwens FR, Duprez DA, De Buyzere ML, et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. *Am J Cardiol*. 1991;68:925–929.
- Hui Y, Hao Y, Chen X, et al. Relationship between some humoral factors and left ventricular hypertrophy in essential hypertension. *Chin Med J Engl*. 1996;109:885–887.
- Helvacı A, Çopur B, Adaş M. Correlation between left ventricular mass index and calcium metabolism in patients with essential hypertension. *Balkan Med J*. 2013;30:85–89.
- Laflamme M-H, Mahjoub H, Mahmut A, et al. Parathyroid hormone is associated with the LV mass after aortic valve replacement. *Heart*. 2014;100:1859–1864.
- Saleh FN, Schirmer H, Sundsfjord J, et al. Parathyroid hormone and left ventricular hypertrophy. *Eur Heart J*. 2003;24:2054–2060.
- Chang WT, Wu CH, Hsu LW, et al. Serum vitamin D, intact parathyroid hormone, and Fetuin A concentrations were associated with geriatric sarcopenia and cardiac hypertrophy. *Sci Rep*. 2017;7:40996–41003.
- Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. *Curr Osteoporos Rep*. 2008;6:77–83.
- Schluter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. *Cardiovasc Res*. 1998;37:34–41.
- Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. *Brit J Nutr*. 1991;65:105–114.
- Bouillon R, Coopmans W, Degroote D, Radoux D, Eliard P. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. *Clin Chem*. 1990;36:271–276.
- Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? *Cardiovasc Ultras*. 2005;3:17.
- Vasconcelos RS, Viégas M, Marques TF, et al. Factors associated with secondary hyperparathyroidism in premenopausal women undergoing Roux-en-Y gastric bypass for the treatment of obesity. *Arq Bras Endocrinol Metabol*. 2010;54:233–238.
- Grethen E, McClintock R, Gupta CE, et al. Vitamin D and hyperparathyroidism in obesity. *J Clin Endocrinol Metab*. 2011;96:1320–1326.
- Andersen T, McNair P, Hyldstrup L, et al. Secondary hyperparathyroidism of morbid obesity regresses during weight reduction. *Metabolism*. 1988;37:425–428.